NCT05579184 - [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 30, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Metastatic Castration-resistant Prostate Cancer, mCRPC

Interventions

DRUG

[177Lu]Ludotadipep

"Patients will receive 100 mCi of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (up to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection"

Trial Locations (1)

Unknown

The Catholic University of Korea, Seoul, St, Mary's Hospital, 222, Banpo-daero, Seocho-gu, Seoul